A recent phase II clinical trial evaluated the antiproliferative potential of oral aspirin associated with programmed cell death protein 1 (PD-1) or pembrolizumab and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or ipilimumab inhibitors in patients with unresectable stage III or stage IV melanoma[42]. This evidence concerns the gene CTLA4 and melanoma.